The use of melanocortin antagonists in cachexia of chronic disease.

Abstract

Cachexia is a wasting syndrome that frequently develops in the setting of chronic diseases including cancer, congestive heart failure, chronic obstructive pulmonary disease, AIDS, renal failure and liver failure. Loss of lean body mass is believed to be a significant factor contributing to morbidity and mortality in these chronic diseases; however, there are currently no treatments available that have proven to be effective in reversing the progressive loss of lean body mass in cachectic patients. Evidence from animal models suggests a compelling link between inflammation, the central melanocortin system and cachexia. This review summarises the current evidence supporting the role of the melanocortin 4 (MC4) receptor subtype in cachexia, and discusses the development and use of small-molecule MC4 antagonists, which have proved to be effective in preventing the loss of lean body mass in animal models of cachexia. MC4 antagonists represent an attractive therapeutic approach for cachexia that may attenuate the loss of lean body mass in cachectic patients.

• Authors: Jarrad M Scarlett, Daniel L Marks
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 14 Issue 10 Pg. 1233-9 (Oct 2005) ISSN: 1744-7658 [Electronic] England
• PMID: 16185165 (Publication Type: Journal Article, Review)

Chemical References

• Pharmaceutical Preparations
• Receptor, Melanocortin, Type 4

Topics

• Animals
• Cachexia (drug therapy, metabolism, physiopathology)
• Chronic Disease
• Humans
• Pharmaceutical Preparations (administration & dosage)
• Receptor, Melanocortin, Type 4 (antagonists & inhibitors, metabolism)